Trial · NCT02914509

Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT

NCT02914509, Phase 3, Completed, Ocular Therapeutix, Inc.; results first posted 2021-10-11

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT. Trials, record NCT02914509. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02914509

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
NCT number: NCT02914509
Status: Completed
Phases: Phase 3
Enrollment: 565 participants, actual
Lead sponsor: Ocular Therapeutix, Inc.
Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Travoprost, Placebo Vehicle
First posted: 2016-09-26
Last updated: 2021-10-11
Results first posted: 2021-10-11

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Mean IOP	Mean IOP at 8AM, 10AM, and 4PM at the 2 Week Visit
Primary	Mean IOP	Mean IOP at 8AM, 10AM, and 4PM at the 6 Week Visit
Primary	Mean IOP	Mean IOP at 8AM, 10AM, and 4PM at the 12 Week Visit
Other	Number of Participants With Serious Adverse Events	Through study completion, an average of 23 months	Number of Participants with Serious Adverse Events

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Mean IOP	Mean IOP at 8AM, 10AM, and 4PM at the 2 Week Visit	mmHg	MEAN
PRIMARY	Mean IOP	Mean IOP at 8AM, 10AM, and 4PM at the 6 Week Visit	mmHg	MEAN
PRIMARY	Mean IOP	Mean IOP at 8AM, 10AM, and 4PM at the 12 Week Visit	mmHg	MEAN
OTHER_PRE_SPECIFIED	Number of Participants With Serious Adverse Events	Through study completion, an average of 23 months	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group20

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Mean IOP	OTX-TP (Sustained Release Travoprost) Intracanalicular Depot	8AM	21	Standard Error 0.2	mmHg
Mean IOP	Placebo Vehicle (PV)	8AM	22.9	Standard Error 0.2	mmHg
Mean IOP	OTX-TP (Sustained Release Travoprost) Intracanalicular Depot	10AM	20.2	Standard Error 0.2	mmHg
Mean IOP	Placebo Vehicle (PV)	10AM	21.9	Standard Error 0.2	mmHg
Mean IOP	OTX-TP (Sustained Release Travoprost) Intracanalicular Depot	4PM	19.5	Standard Error 0.2	mmHg
Mean IOP	Placebo Vehicle (PV)	4PM	21.5	Standard Error 0.2	mmHg
Mean IOP	OTX-TP (Sustained Release Travoprost) Intracanalicular Depot	8AM	21.9	Standard Error 0.2	mmHg
Mean IOP	Placebo Vehicle (PV)	8AM	26.9	Standard Error 0.3	mmHg
Mean IOP	OTX-TP (Sustained Release Travoprost) Intracanalicular Depot	10AM	25.1	Standard Error 0.2	mmHg
Mean IOP	Placebo Vehicle (PV)	10AM	25	Standard Error 0.2	mmHg

1 to 10 of 20Source ClinicalTrials.gov

See all 20 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	OTX-TP	348
Overall Study	STARTED	Placebo Vehicle (PV)	217
Overall Study	COMPLETED	OTX-TP	343
Overall Study	COMPLETED	Placebo Vehicle (PV)	211
Overall Study	NOT COMPLETED	OTX-TP	5
Overall Study	NOT COMPLETED	Placebo Vehicle (PV)	6

Source ClinicalTrials.gov

Adverse events20

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Adverse Event	General disorders	OTX-TP (Sustained Release Travoprost) Intracanalicular Depot	132	348
other	Adverse Event	General disorders	Placebo Vehicle (PV)	65	217
serious	Serious Adverse Event	Nervous system disorders	OTX-TP (Sustained Release Travoprost) Intracanalicular Depot	2	348
serious	Serious Adverse Event	Nervous system disorders	Placebo Vehicle (PV)	0	217
serious	Serious Adverse Event	Infections and infestations	OTX-TP (Sustained Release Travoprost) Intracanalicular Depot	1	348
serious	Serious Adverse Event	Infections and infestations	Placebo Vehicle (PV)	2	217
serious	Serious Adverse Event	Cardiac disorders	OTX-TP (Sustained Release Travoprost) Intracanalicular Depot	1	348
serious	Serious Adverse Event	Cardiac disorders	Placebo Vehicle (PV)	1	217
serious	Serious Adverse Event	Respiratory, thoracic and mediastinal disorders	OTX-TP (Sustained Release Travoprost) Intracanalicular Depot	0	348
serious	Serious Adverse Event	Respiratory, thoracic and mediastinal disorders	Placebo Vehicle (PV)	1	217

1 to 10 of 20Source ClinicalTrials.gov

See all 20 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	OTX-TP (Sustained Release Travoprost) Intracanalicular Depot	1	348
Total, all-cause mortality	Placebo Vehicle (PV)	0	217
Total, other adverse events	OTX-TP (Sustained Release Travoprost) Intracanalicular Depot	132	348
Total, other adverse events	Placebo Vehicle (PV)	65	217
Total, serious adverse events	OTX-TP (Sustained Release Travoprost) Intracanalicular Depot	7	348
Total, serious adverse events	Placebo Vehicle (PV)	6	217

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
OTX-TP (Sustained Release Travoprost) Intracanalicular Depot vs Placebo Vehicle (PV): deaths from any cause	Trial comparisons
OTX-TP (Sustained Release Travoprost) Intracanalicular Depot vs Placebo Vehicle (PV): Number of Participants With Serious Adverse Events	Trial comparisons
OTX-TP (Sustained Release Travoprost) Intracanalicular Depot vs Placebo Vehicle (PV): serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02914509

GET https://conductscience.org/api/trials/v1/NCT02914509/registered

API reference For AI assistants